alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT
      23





CONSENT
      OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING
      FIRM





We
      consent to the incorporation by reference in the Registration Statements (Form
      S-8 No. 3-12043, Form S-8 No. 333-7498, Form S-8 No. 333-111929, Form S-3 No.
      333-84861 and Form S-3 No. 333-117472) of Pilgrim's Pride Corporation, and
      in
      the related Prospectuses, of our reports dated November 15, 2005, with respect
      to the consolidated financial statements and schedule of Pilgrim's Pride
      Corporation, Pilgrim’s Pride Corporation management’s assessment of the
      effectiveness of internal control over financial reporting, and the
      effectiveness of internal control over financial reporting of Pilgrim's Pride
      Corporation, included in this Annual Report (Form 10-K) for the year ended
      October 1, 2005.





ERNST
      & YOUNG LLP














Dallas,
      Texas


November
      15, 2005
<PAGE>

                                                                    EXHIBIT 99.1

AMERICAN ORIENTAL BIOENGINEERING, INC. COMMON STOCK APPROVED FOR LISTING ON THE
                              ARCHIPELAGO EXCHANGE

HONG KONG--(BUSINESS WIRE)--Nov. 11, 2005--American Oriental Bioengineering,
Inc. (AMEX:AOB), an emerging Chinese company that produces and distributes a
broad range of pharmaceutical and nutraceutical products, announced today that
its common stock has been approved for listing on the Archipelago Exchange
(ArcaEx), a facility of the Pacific Exchange, under the symbol AOB. The Company
anticipates that its common stock will commence trading on ArcaEx on November
11, 2005.

"We are pleased to bring this extra level of liquidity to our shareholders, and
additional exposure to potential investors," said Tony (Shujun) Liu, the
Company's Chief Executive Officer.

In addition to being listed on ArcaEx, the Company's common stock will continue
to be listed on the American Stock Exchange under the symbol AOB.

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology
company that uses proprietary processes for producing soybean protein peptide
more efficiently than traditional extracting techniques. These techniques are
used to manufacture and formulate supplemental and medicinal products. Soybean
peptides are used widely in general food, health food products and medicines,
among other applications. The Company also produces Cease-Enuresis Soft Gel, the
only Chinese FDA-approved first grade, prescription medicine that is specially
formulated to help alleviate bed-wetting and incontinence. The Company is a
leading producer of products in both the nutriceuticals and pharmaceuticals
areas in China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events or
performance, and underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to uncertainties
and risks including, but not limited to, product and service demand and
acceptance, changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks contained in
statements filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and whether made
by or on behalf of the company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany the
forward-looking statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or circumstances after
the date hereof.

Contact:

         America Oriental Bioengineering, Inc.
         Lily Li, 917-838-0689 (U.S.)
         +86-451-86688139 (China)
         aobo@bioaobo.com
{"version":"1.0","provider_name":"Federal Maritime Commission","provider_url":"https:\/\/www.fmc.gov","author_name":"Catie-Megan Moran","author_url":"https:\/\/www.fmc.gov\/author\/cmoranfmc-gov\/","title":"Statement of Commissioner Rebecca Dye Ocean Transportation Intermediary Advanced Notice of Proposed Rulemaking","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"76h44ysj64\"><a href=\"\/statement-of-commissioner-rebecca-dye-ocean-transportation-intermediary-advanced-notice-of-proposed-rulemaking\/\">Statement of Commissioner Rebecca Dye Ocean Transportation Intermediary Advanced Notice of Proposed Rulemaking<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"\/statement-of-commissioner-rebecca-dye-ocean-transportation-intermediary-advanced-notice-of-proposed-rulemaking\/embed\/#?secret=76h44ysj64\" width=\"600\" height=\"338\" title=\"“Statement of Commissioner Rebecca Dye Ocean Transportation Intermediary Advanced Notice of Proposed Rulemaking” — Federal Maritime Commission\" data-secret=\"76h44ysj64\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(c,l){\"use strict\";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(\/[^a-zA-Z0-9]\/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=0;o<n.length;o++)n[o].style.display=\"none\";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if(\"link\"===t.message)if(s=l.createElement(\"a\"),a=l.createElement(\"a\"),s.href=r.getAttribute(\"src\"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener(\"message\",c.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",t,!1),c.addEventListener(\"load\",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),a=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),i=l.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n"}
<PAGE>   1

                                                                      EXHIBIT 12

              COMBINED WITH 50% OWNED UNCONSOLIDATED SUBSIDIARIES
               COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

<TABLE>
<CAPTION>
                                                              2000    1999
            FOR THE THREE MONTHS ENDED MARCH 31               ----    ----
                   (DOLLARS IN MILLIONS)
<S>                                                           <C>     <C>
Income from continuing operations...........................  $ 29    $  6
Add
  Interest..................................................    34      36
  Portion of rentals representative of interest factor......     4       4
  Income tax expense and other taxes on income..............    21       3
                                                              ----    ----
          Earnings as defined...............................  $ 88    $ 49
                                                              ====    ====
Interest....................................................  $ 34    $ 36
Interest capitalized........................................     2      --
Portion of rentals representative of interest factor........     4       4
                                                              ----    ----
          Fixed charges as defined..........................  $ 40    $ 40
                                                              ====    ====
Ratio of earnings to fixed charges..........................  2.20    1.23
                                                              ====    ====
</TABLE>
EXHIBIT 32

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Activeworlds Corp. (the "Company") on
Form 10-QSB for the period ending March 31, 2007 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Sean Deson, Chief
Executive Officer and Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of
2002, that to my knowledge:

1.       The Report fully complies with the requirements of section 13(a) or
         15(d) of the Securities Exchange Act of 1934 and

2.       The information contained in the Report fairly presents, in all
         material respects, the financial condition and results of operations of
         the Company.

                                              /s/ Sean Deson
                                              -----------------------------
                                              Sean Deson,
                                              Chief Executive Officer and
                                              Chief Financial Officer

Date: May 18, 2007

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

G.V. HOMES, INC.

v.

STEVE A. FREMPONG AND AGNES 

FREMPONG AND JOHN DOES NO 1 TO 3

PETITION OF: STEVE A. FREMPONG 

AND AGNES FREMPONG

:

:

:

:

:

:

:

:

:

:

:

:

No. 268 EAL 2022

Petition for Allowance of Appeal 

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 25th day of April, 2023, the Petition for Allowance of Appeal is 

DENIED.
| Parent                                   |                                                 |                      |
|------------------------------------------|------------------------------------------------------|---------------------------|
| Roma      Financial Corporation          |                                                 |                      |
|   Subsidiaries                 | State      or OtherJurisdictionOf      Incorporation |  PercentageOwnership |
| Roma      Bank                           | Federal                                              | 100%                      |
| RomAsia      Bank                        | Federal                                              | 89.45%                    |
|                                     |                                                 |                      |
| Subsidiaries of Roma Bank                |                                                 |                      |
| Roma      Capital Investment Corporation | New      Jersey                                      | 100%                      |
| General      Abstract & Title Agency | New      Jersey                                      | 100%                      |
| 84      Hopewell, LLC                    | New      Jersey                                      | 50%                       |
Exhibit 10.1


 


FIRST
AMENDMENT TO LOAN AGREEMENT 


 


This First Amendment to Loan
Agreement (this “Amendment”) is entered into as of January 19, 2022, by and among Specialty Renal Products, Inc.,
a Delaware corporation (“Borrower”), and Nephros, Inc., a Delaware corporation ( “Lender”).


 


WHEREAS, Borrower and Lender are
parties to that certain Loan Agreement dated October 7, 2020 (the “Loan Agreement”), pursuant to which Lender agreed
to lend to Borrower, in accordance with the terms and conditions described in the Loan Agreement, up to a maximum principal amount of
approximately $1,300,000, together with interest thereon (the “Loan”);


 


WHEREAS, Section 2.4 of the Loan
Agreement provides that the Loan may be repaid from time to time by Borrower by that the Final Payment shall be repaid to Lender upon
the earlier to occur of the Final Payment Date or an Event of Default; and


 


WHEREAS, Borrower and Lender desire
to amend the Loan Agreement in order to modify the definition of Final Payment Date to extend such date to March 31, 2023 or such earlier
time as Borrower repays the Loan or Lender converts the Loan balance in connection with a Financing Event.


 


NOW, THEREFORE, in consideration
of the mutual covenants and agreements contained herein, the parties hereby agree as follows:


 


1. Modification of Final Payment
Date. Section 1.1(u) of the Loan Agreement is hereby amended and restated in its entirety as follows:


 


“(u) Final
Payment Date” means the earlier of (i) the date on which the borrower repays the outstanding Balance (together with any other
amounts unpaid under this Agreement) to the Lender pursuant to this Agreement, (ii) the date on which a Financing Event is consummated
(to the extent Lender has not exercised its right to convert the outstanding Balance pursuant to Section 2.9 hereof), and (iii)
March 31, 2023.”


 


2. Miscellaneous. All capitalized
terms used but not defined herein shall have the meanings ascribed to them in the Loan Agreement. Except as amended or modified by this
Amendment, the parties hereby confirm all other terms and provisions of the Loan Agreement and the Note. This Amendment may be executed
in any number of counterparts, each of which shall constitute an original, but all of which together shall constitute one and the same
instrument.


 


[Signature Pages Follow]


 



    	 



     


     


IN WITNESS WHEREOF, the parties have executed
this Amendment as of the date first above written.


 


	 	BORROWER:
	 	 
	 	SPECIALTY RENAL PRODUCTS, INC.
	 	 	 
	 	By:	/s/ Andrew Astor
	 	Name:	 Andrew Astor
	 	Title:	 Chief Executive Officer
	 	 	 
	 	LENDER:
	 	 
	 	NEPHROS, INC.
	 	 	 
	 	By:	/s/ Andrew Astor
	 	Name:	Andrew Astor
	 	Title:	President & CEO
FMCS | 2100 K St. NW, Washington, D.C. 20427 | 202-606-8100 | www.fmcs.gov 

NEWS RELEASE 

Sunday, June 26, 2016 Contact: John Arnold 

For Immediate Release Director of Public Affairs 

Website: www.fmcs.gov Phone: 202-606-8100 

FMCS Statement on Tentative Agreement Between Brigham and Women’s 

Hospital and the Massachusetts Nurses Association 

WASHINGTON, DC—Allison Beck, Director of the Federal Mediation and Conciliation Service (FMCS), 

issued the following statement today on the announcement that a tentative agreement had been 

reached in negotiations between Brigham and Women’s Hospital (BWH) in Boston, MA and the 

Massachusetts Nurses Association (MNA), averting a strike by approximately 3,300 care-givers at the 

hospital planned for Monday, June 27. 

“These were difficult and very lengthy negotiations for the hospital and union representatives, involving 

a number of very complex issues. Thanks to the perseverance and hard work of the negotiating teams, it

appears that an historic work stoppage has been averted at this vital health care facility and operations 

will resume on Monday without disruption,” Ms. Beck stated. 

In addition to recognizing the work of the negotiating teams, Ms. Beck also commended FMCS 

Commissioner Martin Callaghan for his role in assisting the parties. “With only a few days remaining 

before their deadline, Commissioner Callaghan engaged the parties in an intensified, successful 

mediation effort. It was clear that both sides were looking for a way to bridge the differences but 

needed help. Commissioner Callaghan devoted himself through many days, long hours and late night 

sessions assisting the parties in the efforts to find common ground. I commend Commissioner 

Callaghan for his extraordinary work, and we extend our thanks to the parties for their cooperation with 

the FMCS.” 

### 

The Federal Mediation and Conciliation Service, created in 1947, is an independent U.S. government agency whose 

mission is to preserve and promote labor-management peace and cooperation. Headquartered in Washington, DC, 

with 10 regional offices and more than 60 field offices, the agency provides mediation and conflict resolution 

services to industry, government agencies and communities.
{"version":"1.0","provider_name":"Federal Maritime Commission","provider_url":"https:\/\/www.fmc.gov","author_name":"Catie-Megan Moran","author_url":"https:\/\/www.fmc.gov\/author\/cmoranfmc-gov\/","title":"Supply Chain Innovation Teams Report Published","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"8GY2zNnTrV\"><a href=\"\/supply-chain-innovation-teams-report-published\/\">Supply Chain Innovation Teams Report Published<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"\/supply-chain-innovation-teams-report-published\/embed\/#?secret=8GY2zNnTrV\" width=\"600\" height=\"338\" title=\"“Supply Chain Innovation Teams Report Published” — Federal Maritime Commission\" data-secret=\"8GY2zNnTrV\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(c,l){\"use strict\";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(\/[^a-zA-Z0-9]\/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=0;o<n.length;o++)n[o].style.display=\"none\";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if(\"link\"===t.message)if(s=l.createElement(\"a\"),a=l.createElement(\"a\"),s.href=r.getAttribute(\"src\"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener(\"message\",c.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",t,!1),c.addEventListener(\"load\",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),a=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),i=l.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n"}
{"version":"1.0","provider_name":"Federal Maritime Commission","provider_url":"https:\/\/www.fmc.gov","author_name":"Catie-Megan Moran","author_url":"https:\/\/www.fmc.gov\/author\/cmoranfmc-gov\/","title":"Statement of Commissioner Carl W. Bentzel on the Release of the Maritime Transportation Data Initiative Recommendations","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"TC8dh8QMtX\"><a href=\"\/statement-of-commissioner-carl-w-bentzel-on-the-release-of-the-maritime-transportation-data-initiative-recommendations\/\">Statement of Commissioner Carl W. Bentzel on the Release of the Maritime Transportation Data Initiative Recommendations<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"\/statement-of-commissioner-carl-w-bentzel-on-the-release-of-the-maritime-transportation-data-initiative-recommendations\/embed\/#?secret=TC8dh8QMtX\" width=\"600\" height=\"338\" title=\"“Statement of Commissioner Carl W. Bentzel on the Release of the Maritime Transportation Data Initiative Recommendations” — Federal Maritime Commission\" data-secret=\"TC8dh8QMtX\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/*! This file is auto-generated *\/\n!function(c,l){\"use strict\";var e=!1,o=!1;if(l.querySelector)if(c.addEventListener)e=!0;if(c.wp=c.wp||{},c.wp.receiveEmbedMessage);else if(c.wp.receiveEmbedMessage=function(e){var t=e.data;if(!t);else if(!(t.secret||t.message||t.value));else if(\/[^a-zA-Z0-9]\/.test(t.secret));else{for(var r,s,a,i=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),n=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),o=0;o<n.length;o++)n[o].style.display=\"none\";for(o=0;o<i.length;o++)if(r=i[o],e.source!==r.contentWindow);else{if(r.removeAttribute(\"style\"),\"height\"===t.message){if(1e3<(s=parseInt(t.value,10)))s=1e3;else if(~~s<200)s=200;r.height=s}if(\"link\"===t.message)if(s=l.createElement(\"a\"),a=l.createElement(\"a\"),s.href=r.getAttribute(\"src\"),a.href=t.value,a.host===s.host)if(l.activeElement===r)c.top.location.href=t.value}}},e)c.addEventListener(\"message\",c.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",t,!1),c.addEventListener(\"load\",t,!1);function t(){if(o);else{o=!0;for(var e,t,r,s=-1!==navigator.appVersion.indexOf(\"MSIE 10\"),a=!!navigator.userAgent.match(\/Trident.*rv:11\\.\/),i=l.querySelectorAll(\"iframe.wp-embedded-content\"),n=0;n<i.length;n++){if(!(r=(t=i[n]).getAttribute(\"data-secret\")))r=Math.random().toString(36).substr(2,10),t.src+=\"#?secret=\"+r,t.setAttribute(\"data-secret\",r);if(s||a)(e=t.cloneNode(!0)).removeAttribute(\"security\"),t.parentNode.replaceChild(e,t);t.contentWindow.postMessage({message:\"ready\",secret:r},\"*\")}}}}(window,document);\n<\/script>\n"}